Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer - Trial NCT05850637
Access comprehensive clinical trial information for NCT05850637 through Pure Global AI's free database. This Phase 2 trial is sponsored by Prevent Senior Institute and is currently Completed. The study focuses on Breast Cancer Female. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Prevent Senior Institute
Timeline & Enrollment
Phase 2
Jan 30, 2019
Apr 01, 2023
Primary Outcome
Acute toxicity,Late toxicity
Summary
Prospective phase 2 study to evaluate the safety and efficacy of ultra-hypofractionated
 adjuvant radiotherapy in 5 fractions of 5.7 Gy in patients aged over 65 years.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05850637
Non-Device Trial